181 related articles for article (PubMed ID: 26481900)
1. Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis.
Onuma S; Honda H; Kobayashi Y; Yamamoto T; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
Ther Apher Dial; 2015 Dec; 19(6):582-9. PubMed ID: 26481900
[TBL] [Abstract][Full Text] [Related]
2. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
3. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
4. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
[TBL] [Abstract][Full Text] [Related]
5. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
6. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
7. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
[TBL] [Abstract][Full Text] [Related]
8. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
9. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
10. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.
Furukawa T; Okada K; Abe M; Tei R; Oikawa O; Maruyama N; Maruyama T
Int J Mol Sci; 2015 Dec; 16(12):30181-9. PubMed ID: 26694377
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
[TBL] [Abstract][Full Text] [Related]
13. A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.
Oka S; Obata Y; Torigoe K; Torigoe M; Abe S; Muta K; Ota Y; Kitamura M; Kawasaki S; Hirose M; Uramatsu T; Yamashita H; Arai H; Mukae H; Nishino T
Drugs R D; 2017 Sep; 17(3):389-396. PubMed ID: 28547536
[TBL] [Abstract][Full Text] [Related]
14. A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients.
Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998272
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.
Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
Ther Apher Dial; 2014 Oct; 18(5):414-20. PubMed ID: 24456373
[TBL] [Abstract][Full Text] [Related]
16. CERA conversion to darbepoetin alfa in 154 hemodialysis patients.
Dimitrov Y; Rieger J; Krummel T; Petitjean P; Klein A; Chantrel F; Meyer N; Hannedouche T
Int Urol Nephrol; 2020 Oct; 52(10):1979-1985. PubMed ID: 32725508
[TBL] [Abstract][Full Text] [Related]
17. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
18. Shift from darbepoetin-α to continuous erythropoietin receptor activator decreases serum aluminium concentration in patients on hemodialysis.
Liu WS; Chan HL; Lai YT; Yang YH; Teng HW; Liu CK; Li SY; Yang CY; Liu TY; Lin CC
Environ Toxicol Pharmacol; 2016 Jul; 45():108-14. PubMed ID: 27267426
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study.
Kuji T; Toya Y; Fujikawa T; Kakimoto-Shino M; Nishihara M; Shibata K; Tamura K; Hirawa N; Satta H; Kawata S; Kouguchi N; Umemura S
Ther Apher Dial; 2015 Apr; 19(2):131-7. PubMed ID: 25257861
[TBL] [Abstract][Full Text] [Related]
20. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]